Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma

Steven Aller; Andrada Popescu; Sudha Rao; Elaine Morgan; Yasmin Gosiengfiao

doi:10.1002/pbc.23032

Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma

Steven Aller, Andrada Popescu, Sudha Rao, Elaine Morgan, Yasmin Gosiengfiao^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC.

Original language	English (US)
Pages (from-to)	98-100
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	58
Issue number	1
DOIs	https://doi.org/10.1002/pbc.23032
State	Published - Jan 2012

Keywords

MEN2B syndrome
Metastatic medullary thyroid carcinoma
Sorafenib

ASJC Scopus subject areas

Hematology
Oncology
Pediatrics, Perinatology, and Child Health

Access to Document

10.1002/pbc.23032

Cite this

@article{49483f68056142eea4ed7a0cd80099c2,

title = "Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma",

abstract = "Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC.",

keywords = "MEN2B syndrome, Metastatic medullary thyroid carcinoma, Sorafenib",

author = "Steven Aller and Andrada Popescu and Sudha Rao and Elaine Morgan and Yasmin Gosiengfiao",

year = "2012",

month = jan,

doi = "10.1002/pbc.23032",

language = "English (US)",

volume = "58",

pages = "98--100",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma

AU - Aller, Steven

AU - Popescu, Andrada

AU - Rao, Sudha

AU - Morgan, Elaine

AU - Gosiengfiao, Yasmin

PY - 2012/1

Y1 - 2012/1

N2 - Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC.

AB - Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC.

KW - MEN2B syndrome

KW - Metastatic medullary thyroid carcinoma

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=81155144841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155144841&partnerID=8YFLogxK

U2 - 10.1002/pbc.23032

DO - 10.1002/pbc.23032

M3 - Article

C2 - 21721105

AN - SCOPUS:81155144841

SN - 1545-5009

VL - 58

SP - 98

EP - 100

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 1

ER -

Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this